Browsing by Author "Smiseth, Otto A. (7006367337)"
Now showing 1 - 5 of 5
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication How to conduct clinical research in cardiovascular imaging: a primer for clinical cardiologists and researchers—a statement of the European Association of Cardiovascular Imaging (EACVI) of the ESC(2025) ;Muraru, Denisa (57203383206) ;Pontone, Gianluca (8342393600) ;Jurcut, Ruxandra (25228919600) ;Magne, Julien (22938314200) ;Donal, Erwan (7003337454) ;Stankovic, Ivan (57197589922) ;Anagnostopoulos, Constantinos (55400597100) ;Bartko, Philipp E. (36631572100) ;Bijnens, Bart (7005275311) ;Fontana, Marianna (16306839900) ;Galli, Elena (59573629400) ;Michalski, Blazej (14527627100) ;Marra, Martina Perazzolo (9235712600) ;Pezel, Théo (57204933661) ;Rossi, Alexia (36183503300) ;Smiseth, Otto A. (7006367337) ;Van de Veire, Nico (9437143300) ;Edvardsen, Thor (6603263370) ;Petersen, Steffen E. (35430477200)Cosyns, Bernard (57202595662)This statement from the European Association of Cardiovascular Imaging (EACVI) of the ESC aims to address the fundamental principles that guide clinical research in the field of cardiovascular imaging. It provides clinical researchers, cardiology fellows, and PhD students with a condensed, updated, and practical reference document to support them in designing, implementing, and conducting imaging protocols for clinical trials. Although the present article cannot replace formal research training and mentoring, it is recommended reading for any professional interested in becoming acquainted with or participating in clinical trials involving cardiovascular imaging. © The Author(s) 2024. - Some of the metrics are blocked by yourconsent settings
Publication Imaging in patients with cardiovascular implantable electronic devices: part 1—imaging before and during device implantation. A clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI) and the European Heart Rhythm Association (EHRA) of the ESC(2024) ;Stankovic, Ivan (57197589922) ;Voigt, Jens-Uwe (35582937800) ;Burri, Haran (6603663244) ;Muraru, Denisa (57203383206) ;Sade, Leyla Elif (12808884600) ;Haugaa, Kristina Hermann (24733615600) ;Lumens, Joost (23980665500) ;Biffi, Mauro (7007143244) ;Dacher, Jean-Nicolas (54790540100) ;Marsan, Nina Ajmone (23035780700) ;Bakelants, Elise (57193525332) ;Manisty, Charlotte (6504025861) ;Dweck, Marc R. (12783691400) ;Smiseth, Otto A. (7006367337)Donal, Erwan (7003337454)More than 500 000 cardiovascular implantable electronic devices (CIEDs) are implanted in the European Society of Cardiology countries each year. The role of cardiovascular imaging in patients being considered for CIED is distinctly different from imaging in CIED recipients. In the former group, imaging can help identify specific or potentially reversible causes of heart block, the underlying tissue characteristics associated with malignant arrhythmias, and the mechanical consequences of conduction delays and can also aid challenging lead placements. On the other hand, cardiovascular imaging is required in CIED recipients for standard indications and to assess the response to device implantation, to diagnose immediate and delayed complications after implantation, and to guide device optimization. The present clinical consensus statement (Part 1) from the European Association of Cardiovascular Imaging, in collaboration with the European Heart Rhythm Association, provides comprehensive, up-to-date, and evidence-based guidance to cardiologists, cardiac imagers, and pacing specialists regarding the use of imaging in patients undergoing implantation of conventional pacemakers, cardioverter defibrillators, and resynchronization therapy devices. The document summarizes the existing evidence regarding the use of imaging in patient selection and during the implantation procedure and also underlines gaps in evidence in the field. The role of imaging after CIED implantation is discussed in the second document (Part 2). © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Imaging in patients with cardiovascular implantable electronic devices: part 2—imaging after device implantation. A clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI) and the European Heart Rhythm Association (EHRA) of the ESC(2024) ;Stankovic, Ivan (57197589922) ;Voigt, Jens-Uwe (35582937800) ;Burri, Haran (6603663244) ;Muraru, Denisa (57203383206) ;Sade, Leyla Elif (12808884600) ;Haugaa, Kristina Hermann (24733615600) ;Lumens, Joost (23980665500) ;Biffi, Mauro (7007143244) ;Dacher, Jean-Nicolas (54790540100) ;Marsan, Nina Ajmone (23035780700) ;Bakelants, Elise (57193525332) ;Manisty, Charlotte (6504025861) ;Dweck, Marc R. (12783691400) ;Smiseth, Otto A. (7006367337)Donal, Erwan (7003337454)Cardiac implantable electronic devices (CIEDs) improve quality of life and prolong survival, but there are additional considerations for cardiovascular imaging after implantation—both for standard indications and for diagnosing and guiding management of device-related complications. This clinical consensus statement (part 2) from the European Association of Cardiovascular Imaging, in collaboration with the European Heart Rhythm Association, provides comprehensive, up-to-date, and evidence-based guidance to cardiologists, cardiac imagers, and pacing specialists regarding the use of imaging in patients after implantation of conventional pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy (CRT) devices. The document summarizes the existing evidence regarding the role and optimal use of various cardiac imaging modalities in patients with suspected CIED-related complications and also discusses CRT optimization, the safety of magnetic resonance imaging in CIED carriers, and describes the role of chest radiography in assessing CIED type, position, and complications. The role of imaging before and during CIED implantation is discussed in a companion document (part 1). © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Mechanical dyssynchrony as a selection criterion for cardiac resynchronization therapy: Design of the AMEND-CRT trial(2024) ;Puvrez, Alexis (57222530285) ;Duchenne, Jürgen (55942794300) ;Donal, Erwan (7003337454) ;Gorcsan, John (7006474256) ;Patel, Hitesh C. (55911436600) ;Marwick, Thomas H. (7102424966) ;Smiseth, Otto A. (7006367337) ;Søgaard, Peter (7005085172) ;Stankovic, Ivan (57197589922) ;Diogo, Pedro G. (57222475545) ;Vörös, Gábor (56366425000)Voigt, Jens-Uwe (35582937800)Aims: One third of patients do not improve after cardiac resynchronization therapy (CRT). Septal flash (SF) and apical rocking (ApRock) are deformation patterns observed on echocardiography in most patients eligible for CRT. These markers of mechanical dyssynchrony have been associated to improved outcome after CRT in observational studies and may be useful to better select patients. The aim of this trial is to investigate whether the current guideline criteria for selecting patients for CRT should be modified and include SF and ApRock to improve therapy success rate, reduce excessive costs and prevent exposure to device-related complications in patients who would not benefit from CRT. Methods: The AMEND-CRT trial is a multicentre, randomized, parallel-group, double-blind, sham-controlled trial with a non-inferiority design. The trial will include 578 patients scheduled for CRT according to the 2021 ESC guidelines who satisfy all inclusion criteria. The randomization is performed 1:1 to an active control arm (‘guideline arm’) or an experimental arm (‘echo arm’). All participants receive a device, but in the echo arm, CRT is activated only when SF or ApRock or both are present. The outcome of both arms will be compared after 1 year. The primary outcome measures are the average change in left ventricular end-systolic volume and patient outcome assessed using a modified Packer Clinical Composite Score. Conclusions: The findings of this trial will redefine the role of echocardiography in CRT and potentially determine which patients with heart failure and a prolonged QRS duration should receive CRT, especially in patients who currently have a class IIa or class IIb recommendation. © 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. - Some of the metrics are blocked by yourconsent settings
Publication Multimodality imaging in patients with heart failure and preserved ejection fraction: An expert consensus document of the European Association of Cardiovascular Imaging(2022) ;Smiseth, Otto A. (7006367337) ;Morris, Daniel A. (37056154300) ;Cardim, Nuno (7004229183) ;Cikes, Maja (55895105900) ;Delgado, Victoria (24172709900) ;Donal, Erwan (7003337454) ;Flachskampf, Frank A (7006759790) ;Galderisi, Maurizio (57203882101) ;Gerber, Bernhard L (7102014010) ;Gimelli, Alessia (6603051677) ;Klein, Allan L (7402142693) ;Knuuti, Juhani (57210225163) ;Lancellotti, Patrizio (7003380556) ;Mascherbauer, Julia (6507613914) ;Milicic, Davor (56503365500) ;Seferovic, Petar (6603594879) ;Solomon, Scott (7401460954) ;Edvardsen, Thor (6603263370) ;Popescu, Bogdan A. (37005664700) ;Bertrand, Philippe B. (55754216700) ;Dweck, Marc (12783691400) ;Haugaa, Kristina H. (24733615600) ;Sade, Leyla Elif (12808884600) ;Stankovic, Ivan (58102398200) ;Ha, Jong-Won (57965523300) ;Nagueh, Sherif (7006967559) ;Oh, Jae K (7402155034) ;Ohte, Nobuyuki (55630495700)Cosyns, Bernard (57202595662)Nearly half of all patients with heart failure (HF) have a normal left ventricular (LV) ejection fraction (EF) and the condition is termed heart failure with preserved ejection fraction (HFpEF). It is assumed that in these patients HF is due primarily to LV diastolic dysfunction. The prognosis in HFpEF is almost as severe as in HF with reduced EF (HFrEF). In contrast to HFrEF where drugs and devices are proven to reduce mortality, in HFpEF there has been limited therapy available with documented effects on prognosis. This may reflect that HFpEF encompasses a wide range of different pathological processes, which multimodality imaging is well placed to differentiate. Progress in developing therapies for HFpEF has been hampered by a lack of uniform diagnostic criteria. The present expert consensus document from the European Association of Cardiovascular Imaging (EACVI) provides recommendations regarding how to determine elevated LV filling pressure in the setting of suspected HFpEF and how to use multimodality imaging to determine specific aetiologies in patients with HFpEF. © 2021 Published on behalf of the European Society of Cardiology. All rights reserved.
